Commodore Capital LP Acquires 333,340 Shares of Oruka Therapeutics, Inc. $ORKA

Commodore Capital LP lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 23.5% during the third quarter, Holdings Channel reports. The fund owned 1,753,054 shares of the company’s stock after buying an additional 333,340 shares during the quarter. Oruka Therapeutics comprises 1.6% of Commodore Capital LP’s investment portfolio, making the stock its 22nd largest position. Commodore Capital LP’s holdings in Oruka Therapeutics were worth $33,711,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new stake in Oruka Therapeutics in the first quarter valued at $2,505,000. Geode Capital Management LLC increased its position in Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after buying an additional 354,821 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $68,000. Intech Investment Management LLC acquired a new position in Oruka Therapeutics during the 2nd quarter worth approximately $168,000. Finally, JPMorgan Chase & Co. boosted its holdings in Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ORKA. Stifel Nicolaus upped their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday. Barclays lifted their price objective on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Friday. Guggenheim restated a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a research report on Friday. Finally, Wedbush reiterated an “outperform” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.67.

Oruka Therapeutics Trading Up 25.0%

Shares of NASDAQ:ORKA opened at $40.00 on Friday. The stock has a market cap of $1.94 billion, a PE ratio of -21.51 and a beta of -0.38. The stock’s fifty day simple moving average is $32.92 and its two-hundred day simple moving average is $27.59. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.16. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 21,000 shares of company stock valued at $663,530. Corporate insiders own 24.69% of the company’s stock.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.